Limits...
The Application of Fluorescence Optical Imaging in Systemic Sclerosis.

Pfeil A, Drummer KF, Böttcher J, Jung C, Oelzner P, Renz DM, Franz M, Hansch A, Wolf G - Biomed Res Int (2015)

Bottom Line: After seven days of either iloprost or alprostadil therapy a significant reduction in the ICG was observed which ranged from 40.9% to 24.7%.The study demonstrates that the FOI technique is able to visualize soft-tissue inflammation with both high sensitivity and specificity.The anti-inflammatory therapeutic effects of iloprost were slightly stronger than alprostadil.

View Article: PubMed Central - PubMed

Affiliation: Department of Internal Medicine III, Jena University Hospital, Friedrich Schiller University Jena, Erlanger Allee 101, 07747 Jena, Germany.

ABSTRACT

Objective: The aim of this study was to visualize soft tissue inflammation using FOI on patients with Systemic Sclerosis (SSc) characterized by SSc-related Raynaud's phenomenon and to detect the therapeutic response to treatment with iloprost or alprostadil.

Methods: Twenty-one patients with SSc and Raynaud's phenomenon and twenty-six healthy controls were prospectively included. The SSc patients were intravenously treated with iloprost or alprostadil over seven days. FOI was performed at baseline and after seven days using an intravenous application of indocyanine green (ICG). The hands were divided into nineteen segments per hand. All segments were quantitatively evaluated to determine changes in ICG.

Results: The sensitivity and specificity of FOI in the detection of ICG enhancement in patients with SSc were 95% versus 96%. At baseline, 31.5% hand segments showed ICG enhancement. After seven days of either iloprost or alprostadil therapy a significant reduction in the ICG was observed which ranged from 40.9% to 24.7%.

Conclusion: The study demonstrates that the FOI technique is able to visualize soft-tissue inflammation with both high sensitivity and specificity. The anti-inflammatory therapeutic effects of iloprost were slightly stronger than alprostadil. FOI offers promising benefits in the diagnosis and therapy of patients with SSc-associated Raynaud's phenomenon.

No MeSH data available.


Related in: MedlinePlus

(a) Initial imaging of the enhancement of indocyanine green by fluorescence optical imaging as a marker of inflammatory activity in patients with SSc and associated Raynaud's phenomenon before the application of alprostadil (day 0, baseline) and (b) after the alprostadil therapy (day seven), corresponding to the reduced enhancement of indocyanine green after the iloprost therapy over 7 days [12].
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4555360&req=5

fig2: (a) Initial imaging of the enhancement of indocyanine green by fluorescence optical imaging as a marker of inflammatory activity in patients with SSc and associated Raynaud's phenomenon before the application of alprostadil (day 0, baseline) and (b) after the alprostadil therapy (day seven), corresponding to the reduced enhancement of indocyanine green after the iloprost therapy over 7 days [12].

Mentions: All patients were treated with intravenous application of iloprost or alprostadil over seven consecutive days. By comparing the ICG enhancement at day 0 and after the application of iloprost over seven days, a significantly (p < 0.05) reduced enhancement of ICG in 166 versus 98 hand segments at the end of therapy was observed. A reduction of −40.9% (p < 0.05) in ICG enhancement between both time points was observed using iloprost. Regarding the alprostadil group a decrease of ICG enhancement with −24.7% between baseline (85 hand segments) and day 7 (64 hand segments) was verified (see Table 2 and Figure 2).


The Application of Fluorescence Optical Imaging in Systemic Sclerosis.

Pfeil A, Drummer KF, Böttcher J, Jung C, Oelzner P, Renz DM, Franz M, Hansch A, Wolf G - Biomed Res Int (2015)

(a) Initial imaging of the enhancement of indocyanine green by fluorescence optical imaging as a marker of inflammatory activity in patients with SSc and associated Raynaud's phenomenon before the application of alprostadil (day 0, baseline) and (b) after the alprostadil therapy (day seven), corresponding to the reduced enhancement of indocyanine green after the iloprost therapy over 7 days [12].
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4555360&req=5

fig2: (a) Initial imaging of the enhancement of indocyanine green by fluorescence optical imaging as a marker of inflammatory activity in patients with SSc and associated Raynaud's phenomenon before the application of alprostadil (day 0, baseline) and (b) after the alprostadil therapy (day seven), corresponding to the reduced enhancement of indocyanine green after the iloprost therapy over 7 days [12].
Mentions: All patients were treated with intravenous application of iloprost or alprostadil over seven consecutive days. By comparing the ICG enhancement at day 0 and after the application of iloprost over seven days, a significantly (p < 0.05) reduced enhancement of ICG in 166 versus 98 hand segments at the end of therapy was observed. A reduction of −40.9% (p < 0.05) in ICG enhancement between both time points was observed using iloprost. Regarding the alprostadil group a decrease of ICG enhancement with −24.7% between baseline (85 hand segments) and day 7 (64 hand segments) was verified (see Table 2 and Figure 2).

Bottom Line: After seven days of either iloprost or alprostadil therapy a significant reduction in the ICG was observed which ranged from 40.9% to 24.7%.The study demonstrates that the FOI technique is able to visualize soft-tissue inflammation with both high sensitivity and specificity.The anti-inflammatory therapeutic effects of iloprost were slightly stronger than alprostadil.

View Article: PubMed Central - PubMed

Affiliation: Department of Internal Medicine III, Jena University Hospital, Friedrich Schiller University Jena, Erlanger Allee 101, 07747 Jena, Germany.

ABSTRACT

Objective: The aim of this study was to visualize soft tissue inflammation using FOI on patients with Systemic Sclerosis (SSc) characterized by SSc-related Raynaud's phenomenon and to detect the therapeutic response to treatment with iloprost or alprostadil.

Methods: Twenty-one patients with SSc and Raynaud's phenomenon and twenty-six healthy controls were prospectively included. The SSc patients were intravenously treated with iloprost or alprostadil over seven days. FOI was performed at baseline and after seven days using an intravenous application of indocyanine green (ICG). The hands were divided into nineteen segments per hand. All segments were quantitatively evaluated to determine changes in ICG.

Results: The sensitivity and specificity of FOI in the detection of ICG enhancement in patients with SSc were 95% versus 96%. At baseline, 31.5% hand segments showed ICG enhancement. After seven days of either iloprost or alprostadil therapy a significant reduction in the ICG was observed which ranged from 40.9% to 24.7%.

Conclusion: The study demonstrates that the FOI technique is able to visualize soft-tissue inflammation with both high sensitivity and specificity. The anti-inflammatory therapeutic effects of iloprost were slightly stronger than alprostadil. FOI offers promising benefits in the diagnosis and therapy of patients with SSc-associated Raynaud's phenomenon.

No MeSH data available.


Related in: MedlinePlus